| 產(chǎn)品名稱 | Apremilast - CC 10004 |
| 產(chǎn)品貨號 | Axon 1957 CAS [608141-41-9] MF C22H24N2O7SMW 460.50 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Orally active inhibitor of phosphodiesterase-4 (PDE4); an investigational drug for ankylosing spondylitis, psoriasis, and psoriatic arthritis. Apremilast reduces TNF-α production from human synovial cells and significantly suppresses experimental arthritis References Certificates Categories Extra info K Papp et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet, 2012, 380 (9843), 738-746. ? P Schafer. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol. 2012, 83 (12), 1583–1590.? ? FE McCann et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res. Ther. 2010, 12(3), R107.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CNS Immunology Pain & Inflammation EC 3.1.4.53 PDE PDE4 inhibitor Chemical name (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide Parent CAS No. [608141-41-9] Order Size Unit Price Stock 5 mg €105.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Apremilast - CC 10004Axon 1957 CAS [608141-41-9] MF C22H24N2O7S
Description
Orally active inhibitor of phosphodiesterase-4 (PDE4); an investigational drug for ankylosing spondylitis, psoriasis, and psoriatic arthritis. Apremilast reduces TNF-α production from human synovial cells and significantly suppresses experimental arthritis
PDE4 inhibitor
Chemical name(S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide Parent CAS No.[608141-41-9] |
| 產(chǎn)品資料 |
